SG Americas Securities’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

SG Americas Securities’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,195	Closed	-$28K	–	3451
2023 Q1	$28K	Buy	15,195 +1,560	+11%	+$1.93K	﹤0.01%	3125
2022 Q4	$15K	Buy	13,635 +140	+1%	+$199	﹤0.01%	2958
2022 Q3	$32K	Sell	13,495 -2,273	-14%	-$8.05K	﹤0.01%	3056
2022 Q2	$48K	Buy	+15,768	New	+$76.7K	﹤0.01%	3269
2021 Q4	–	Sell	-23,393	Closed	-$174K	–	3941
2021 Q3	$174K	Buy	+23,393	New	+$145K	﹤0.01%	3321
2019 Q1	–	Sell	-16,213	Closed	-$55K	–	3706
2018 Q4	$55K	Buy	+16,213	New	+$75.7K	﹤0.01%	2813
2018 Q1	–	Sell	-23,079	Closed	-$294K	–	3633
2017 Q4	$294K	Buy	+23,079	New	+$339K	﹤0.01%	2193

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

SG Americas Securities's JNCE Position: Q2 2023 in Review

SG Americas Securities sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 15,195 shares — an estimated $28K sold.

SG Americas Securities first reported a position in JNCE in Q4 2017 and held it in 7 quarters. The position peaked at $294K in Q4 2017. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

SG Americas Securities reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
SG Americas Securities sold 15,195 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $28K.
SG Americas Securities first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
SG Americas Securities's Jounce Therapeutics, Inc. Common Stock position peaked at $294K in Q4 2017.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on SG Americas Securities's 13F filing for Q2 2023, filed 10 Jul 2023.